In calendar year 2023, 340B covered entities purchased $66.3 billion in covered outpatient drugs under the 340B Program. The program enables safety-net providers to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services for the communities that they serve. The information below details the aggregate 340B purchases by covered entity type in 2023.| www.hrsa.gov
The 340B Drug Pricing Program has been used to inflate the profits of hospitals and pharmacies rather than providing savings.| Council For Citizens Against Government Waste
STOP THE SPECIAL INTEREST FEEDING FRENZY!| Council For Citizens Against Government Waste
CBO examines drug purchases made through the 340B program in 2021, growth in such purchases from 2010 to 2021, and factors that contributed to that growth. CBO also assesses how the 340B program affects the federal budget.| Congressional Budget Office
CAGW submits comments to HHS and HRSA regarding the 340B Rebate Model Pilot Program.| Citizens Against Government Waste
The Committee on Energy and Commerce is the oldest standing legislative committee in the U.S. House of Representatives and is vested with the broadest jurisdiction of any congressional authorizing committee.| House Committee on Energy and Commerce
